FDA
Home Page | Search FDA Site |
FDA A-Z Index | Contact FDA
On June 30, 2003, FDA transferred some of the therapeutic biological products
that had been reviewed and regulated by the Center for Biologics Evaluation
and Research (CBER) to the Center for Drug Evaluation and Research (CDER). CDER
now has regulatory responsibility, including premarket review and continuing
oversight, over the transferred products. In regulating the products assigned
to them, CBER and CDER will consult with each other regularly and whenever necessary.
On October 1, 2003, the staff comprising CBER’s Office of Therapeutics
Research and Review also transferred to CDER. CDER created two new offices to
accommodate the former CBER staff:
For further information about the organizational structure of the two new offices in CDER, see www.fda.gov/cder/biologics/default.htm.
The lists below identify categories of therapeutic biological products transferred from CBER to CDER, and categories of therapeutic biological products remaining in CBER. Please note that the CBER list contains only a portion of the products CBER currently regulates; this list contains products that are closely related in chemical structure to products that transferred to CDER, e.g. therapeutic proteins and polysaccharides. Products are included on the CBER list as a means of clarifying the products that transferred and those that did not.
The lists above contain some combination products comprised of a biological product component with a device and/or drug component, though such products are not specifically identified. Combination products are assigned to a Center for review and regulation in accordance with the products’ primary mode of action.2 When a product’s primary mode of action is attributable to a type of biological product assigned to CDER, the product will be assigned to CDER. Similarly, when a product’s primary mode of action is attributable to a type of biological product assigned to CBER, the product will be assigned to CBER. For further information about combination products, see www.fda.gov/oc/combination, or contact the Office of Combination Products at 301-427-1934, or combination@fda.gov.
Questions about the assignment of specific products to CBER or CDER should be directed to the center jurisdiction officers at:
CDER Ombudsman ......................... 301-594-5480
CBER Ombudsman ......................... 301-827-0379
_______________________________________________
Footnotes
1Growth factors, cytokines, and monoclonal antibodies intended to mobilize, stimulate, decrease or otherwise alter the production of hematopoietic cells in vivo, for the purpose of being harvested for use in the production of a therapeutic cellular or blood product, may be regulated in combination with the therapeutic cellular or blood product, as appropriate. Sponsors of products that fit this description should contact the center jurisdiction officers listed below for guidance on appropriate center assignment.
2 See 21 U.S.C. § 353(g), section 503(g) of the Federal Food, Drug, and Cosmetic Act.